Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UROLITINN is a herbal dietary supplement developed by INNventa Pharm for the prevention and treatment of urolithiasis (kidney stones) and various urinary tract conditions. It is a complex botanical formulation obtained through the hydrodistillation of eight medicinal plants: *Equisetum arvense* (horsetail), *Spergularia rubra* (red sandwort), *Peumus boldus* (boldo leaf), *Opuntia ficus-indica* (Indian fig flower), *Sideritis angustifolia* (mountain tea), *Rosmarinus officinalis* (rosemary), *Cynodon dactylon* (Bermuda grass rhizome), and *Melissa officinalis* (lemon balm). The product acts synergistically to stimulate diuresis, facilitating the removal of salt crystals and stones from the urinary tract, while also providing antispasmodic and analgesic effects to control pain. It is indicated for urolithiasis, urinary tract infections (such as cystitis, urethritis, and pyelonephritis), and symptoms like dysuria, polyuria, nocturia, and urinary incontinence. The product is marketed as an oral solution and has a reported history of use spanning over 90 years.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on UROLITINN.